Evidence map›Paper›PMID 42881190›Full record

Observational studyNature communications2026

Plasma autoantibody profiling via PhIP-seq and machine learning for diagnosis of esophageal squamous cell carcinoma.

Ming-Jun Jin, Yi-Wei Xu, Xiong-Xing He, Ming-Liang Ma, Wen-Zhi Wu, Jun-Feng Zhang, De-Yuan Pan, Shu-Xian Chen, Geng Wang, Qing-Feng Huang and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ming-Jun Jin *The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.ORCID http://orcid.org/0009-0003-8284-8960
Yi-Wei Xu *Department of Clinical Laboratory Medicine, Chaoshan Branch of State Key Laboratory for Esophageal Cancer Prevention and Treatment, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed) / Guangdong Engineering Technology Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Xiong-Xing He *The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Ming-Liang MaAbCode Biotechnology Co., Ltd, Shanghai, China.
Wen-Zhi WuDepartment of Clinical Laboratory Medicine, Chaoshan Branch of State Key Laboratory for Esophageal Cancer Prevention and Treatment, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed) / Guangdong Engineering Technology Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.ORCID http://orcid.org/0009-0003-3084-9443
Jun-Feng ZhangAbCode Biotechnology Co., Ltd, Shanghai, China.
De-Yuan PanThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Shu-Xian ChenDepartment of Digestive Endoscopy, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Geng WangGuangdong Esophageal Cancer Research Institute, Shantou Sub-center, Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.ORCID http://orcid.org/0000-0002-8976-2487
Qing-Feng HuangThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.ORCID http://orcid.org/0000-0003-1594-8884
Su-Zuan ChenDepartment of Digestive Endoscopy, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
He-Cheng HuangShantou Central Hospital, Shantou, Guangdong, China.
Yu-Hui PengDepartment of Clinical Laboratory Medicine, Chaoshan Branch of State Key Laboratory for Esophageal Cancer Prevention and Treatment, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed) / Guangdong Engineering Technology Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Sheng-Ce TaoShanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-9210-1823
Yang LiAbCode Biotechnology Co., Ltd, Shanghai, China. yang.li@abcodebio.com.ORCID http://orcid.org/0000-0002-3182-6169
En-Min LiThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. nmli@stu.edu.cn.ORCID http://orcid.org/0000-0001-6375-3614
Li-Yan XuThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Institute of Oncologic Pathology, Department of Pathology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. lyxu@stu.edu.cn.ORCID http://orcid.org/0000-0002-1618-4292

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis of esophageal squamous cell carcinoma (ESCC) is crucial for improving patient survival. This study employed phage immunoprecipitation sequencing (PhIP-Seq) to comprehensively profile circulating autoantibodies using 1039 plasma samples from a multicenter cohort. Through integrated machine learning approaches, we identified a panel of core antigenic peptides that effectively distinguish ESCC patients from normal controls. The established diagnostic model, based on XGBoost and featuring autoantibodies against antigens such as KMT2C and INPP4B, demonstrated robust performance across multiple validation sets. It achieved area under the curve (AUC) values of 0.912 (95% CI: 0.878-0.946) in the training set, 0.782 (95% CI: 0.696-0.868) in the internal validation set, 0.809 (95% CI: 0.762-0.856) and 0.729 (95% CI: 0.570-0.889) in two independent external cohorts, respectively. Furthermore, the model showed preliminary potential in assessing treatment response, suggesting its possible utility in disease monitoring, although this finding requires independent validation in larger prospective cohorts. This work provides a framework for non-invasive ESCC detection and precision management.

Indexed as

AutoantibodiesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaMachine LearningAgedArea Under CurveBiomarkers, TumorBoosting Machine Learning AlgorithmsFemaleHumansMaleMiddle AgedAutoantibodiesBiomarkers, Tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.